Epidermal growth factor receptor non-small cell lung cancer (EGFR NSCLC) is a lung cancer subtype driven by EGFR gene mutations, leading to rapid tumor growth. It's prevalent particularly in Asian ...

OPERA-02: a phase 3 randomized, double-blind, active-controlled study of palazestrant with ribociclib versus letrozole with ribociclib for the first-line treatment of ER+, HER2- advanced breast cancer ...

Mayo Clinic researchers have discovered a key reason why certain breast cancers might not respond to an important new class ...

NOTE. Percentage values in the cells may not sum up to 100% because of rounding. Bold indicates P < .05. Abbreviations: Bev, bevacizumab; ECOG-PS, Eastern Cooperative Oncology Group Performance Status ...

This subtype represents between 2% and 4% of NSCLC patients. Outcomes are generally suboptimal for HER2-mutant disease for ...

The landscape shifted dramatically with the emergence of fam-trastuzumab deruxtecan-nxki (T-DXd), an ADC that combines trastuzumab with a potent topoisomerase I inhibitor payload, deruxtecan, via a ...

ArriVent BioPharma, Inc. (($AVBP)) announced an update on their ongoing clinical study. ArriVent BioPharma, Inc. is conducting a pivotal clinical ...

The decision by the Canadian regulator is supported by the findings from the Phase III DESTINY-Breast06 study.

Patients with chemorefractory metastatic colorectal cancer derive no overall survival benefit from giving anti-EGFR ...

The EMERALD trial investigators randomly assigned 478 patients with ER+, HER2- advanced breast cancer on a 1:1 basis to receive elacestrant or physician’s choice of standard therapy, which was defined ...